top of page

Innately curing cancer with Immuno-Modulatory Alpha Neutrophils (IMANs)

We are world leaders in neutrophil immunotherapies

LIfT BioSciences is a global leader in neutrophil immunotherapies for rejuvenating immune competence. The platform is initially being focused on overcoming treatment resistance in cancer but will also be deployed in longevity, auto-immune, anti-microbial resistance and dementia.

Led by Dr. Tony De FougerollesFounding CSO of Moderna, CSO Ablynx, VP Research Alnylam; centrally involved in bringing 2 Nobel prize winning discoveries to market.  LIfT® is closing a £22.5m 2nd close + with £10m done in 1st close and having just secured a further £11m in grant money. The funding takes LIft through Phase I trials with interims in early 2027. LIfT also has early iPSC CAR-IMAN & tri-specific innate and adaptive immune engager pharma collaborations.

UK Office
London BioScience Innovation Centre
 

2 Royal College Street
London

NW1 0NH
United Kingdom

​​​​

Company Reg: 09277638

Ireland Office
Eolaíocht Bhitheach LIfT Teoranta

Páirc Na Meán, Spiddal West 

An Spidéal

Co. Galway

H91 CH01

Ireland

US Office
Lift Biosciences Inc

265 Franklin Street

Suite 1702

Boston 02110

MA

United States of America

  • LIfTBio on Facebook
  • X
  • CEO's Linked-in

Copyright © 2025 LIfT BioSciences Ltd. All Rights Reserved.

bottom of page